Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, [1] but also showing significant inhibition of other PDE subtypes.

2022年6月10日 · Ibudilast (MN-166) is an orally available small molecule that is being developed for the treatment of relapsing and progressive forms of multiple sclerosis (MS). It works as an anti-inflammatory,...

2018年8月29日 · Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood–brain barrier, with potential...

2007年11月18日 · Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients...

Ibudilast is a nonselective phosphodiesterase inhibitor that shows potential neuroprotective properties in multiple sclerosis patients by reducing brain volume change and the formation of persistent lesions.

Ibudilast, an anti-inflammatory drug firstly developed as an asthma treatment, is a cyclic nucleotide phosphodiesterases (PDEs) inhibitor, which mainly acts by increasing the amount of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), while downregulating the pro-inflammatory factors, such as tumor necrosis factor-...

2024年9月30日 · The company is now testing ibudilast in a Phase 2b/3 trial called COMBAT-ALS (NCT04057898). It’s enrolling about 230 ALS patients at several locations in the U.S. and Canada. In addition to standard ALS medications, participants will assigned ibudilast twice daily, or a placebo, for one year.

2024年9月24日 · MediciNova will provide MN-166, which it’s developing using the active pharmaceutical ingredient (API) of ibudilast, an anti-inflammatory drug, currently used in Japan. The drug's ability to penetrate the central nervous system, block harmful proteins and stimulate cell repair makes it a possible option for ALS treatment.

Ibudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel pharmacotherapy for alcohol use disorder (AUD).

Ibudilast, a neuroimmune modulator, shows promise as a pharmacotherapy for alcohol use disorder (AUD). In vivo administration of ibudilast reduces the expression of pro-inflammatory cytokines in animal models, but its effects on markers of inflammation in humans are unknown.